Sirt6 deficiency in mast cells promotes adipose fibroinflammation in obesity through galectin-3 signaling

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Mast cells (MCs) play a key role in obesity and insulin resistance, though the mechanisms driving adipose dysfunction remain unclear. We find that Sirt6 expression in MCs decreases with obesity in both male mice and humans. Selective depletion of Sirt6 in MCs worsens inflammation, fibrosis, and metabolic dysfunction in diet-induced obesity. Adoptive transfer of MC-deficient KitW-sh/W-sh mice with Sirt6-deficient MCs leads to greater weight gain on a high-fat diet compared to transfer with wild-type MCs; however, this effect is absent when the transferred MCs lack both Sirt6 and galectin-3. Mechanistically, Sirt6 deacetylates H3K9 at the Lgals3 promoter, inhibiting galectin-3 production and protecting against M1 macrophage polarization and adipose tissue fibrosis. Single-cell RNA sequencing reveals a fibroinflammatory MC subpopulation dominating in the adipose tissue of Sirt6 knockout mice. Targeting Sirt6 activation or galectin-3 inhibition in MCs may represent a therapeutic approach for obesity-associated adipose fibroinflammation and insulin resistance.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.